Ownership and insider activity for Anika Therapeutics, Inc. (ANIK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
Price
| Price | $20.81 |
| Market Cap | $278M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-04 | Fischetti Gary P | P-Purchase | 1,000 | $20K |
| 2026-08-03 | Fischetti Gary P | P-Purchase | 1,000 | $21K |
| 2026-06-18 | Fischetti Gary P | A-Award | 10,402 | |
| 2026-06-18 | HENNEMAN JOHN B III | A-Award | 10,402 | |
| 2026-06-18 | Richard Stephen | A-Award | 10,402 | |
| 2026-06-18 | Capper Joseph H | A-Award | 10,402 | |
| 2026-06-18 | CONLEY SHERYL L | A-Award | 10,402 | |
| 2026-06-03 | Griffin Stephen D. | M-Exempt | 12,840 | |
| 2026-06-03 | Griffin Stephen D. | F-InKind | 3,769 | $54K |
| 2026-06-03 | Griffin Stephen D. | M-Exempt | 12,840 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.3M | $133.3M | $89.0M | $157.5M | $95.8M | $94.4M | $86.3M | $68.7M | $55.6M | $57.5M |
| Short-term Investments | $20.5M | $24.0M | $70.0M | $27.5M | $2.5M | 0 | 0 | 0 | 0 | 0 |
| Receivables | $27.6M | $23.8M | $20.8M | $23.1M | $24.1M | $29.8M | $34.6M | $26.4M | $23.6M | $23.7M |
| Inventory | $16.0M | $22.0M | $21.3M | $22.0M | $46.2M | $36.0M | $39.8M | $24.4M | $23.8M | $18.8M |
| Total Current Assets | $170.4M | $206.3M | $202.9M | $234.3M | $177.4M | $168.5M | $169.5M | $163.3M | $113.7M | $103.4M |
| Property, Plant & Equipment | $52.3M | $56.2M | $54.1M | $73.6M | $73.2M | $68.6M | $79.0M | $65.0M | $64.7M | $66.3M |
| Goodwill | $7.2M | $8.2M | $7.9M | $7.7M | $8.4M | $7.8M | $7.3M | $7.6M | $7.1M | $8.1M |
| Intangible Assets | $10.2M | $10.6M | $9.2M | $7.6M | $91.2M | $82.4M | $74.6M | $2.6M | $2.5M | $1.6M |
| Total Assets | $240.2M | $282.6M | $279.0M | $330.7M | $365.6M | $347.5M | $349.1M | $270.6M | $202.7M | $190.3M |
| Accounts Payable | $2.3M | $6.7M | $3.1M | $3.8M | $9.0M | $7.6M | $9.1M | $6.2M | $5.6M | $6.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $8.8M | $13.1M | $11.3M | $16.3M | $36.9M | $29.8M | $27.9M | $31.1M | $23.3M | $21.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.2M |
| Total Liabilities | $17.5M | $19.1M | $15.4M | $42.3M | $93.2M | $60.5M | $63.6M | $58.4M | $48.8M | $46.8M |
| Retained Earnings | $168.2M | $199.5M | $218.2M | $245.4M | $221.4M | $225.6M | $210.7M | $128.1M | $71.7M | $60.8M |
| Total Equity | $222.8M | $263.5M | $263.6M | $288.4M | $272.4M | $287.1M | $285.6M | $212.3M | $154.0M | $143.5M |
| Total Debt | 0 | 0 | 0 | $22.5M | $22.5M | $21.0M | $30.9M | $27.7M | $25.9M | $26.2M |
| Net Debt | -$124.8M | -$157.3M | -$159.0M | -$162.4M | -$75.9M | -$73.4M | -$55.4M | -$41.0M | -$29.7M | -$31.2M |
| Working Capital | $161.6M | $193.3M | $191.7M | $218.0M | $140.5M | $138.7M | $141.6M | $132.2M | $90.3M | $81.5M |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 4.48 |
Profitability
| Return on Equity | -2.70% |
| Return on Invested Capital | -3.17% |
| Return on Assets | -2.06% |
| Gross Margin | 62.16% |
| Operating Margin | -4.24% |
| Net Margin | -3.14% |
Related companies: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Specialties
More sections of ANIK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks